TY  - GEN
AU  - Carrato, A
AU  - Benavides, M
AU  - Massuti, B
AU  - Ferreiro-Monteagudo, R
AU  - Garcia Alfonso, Pilar
AU  - Falcó, Esther
AU  - Reboredo, M
AU  - Cano, T
AU  - Gallego, Javier
AU  - Vieitez, JM
AU  - Layos, L
AU  - Salud, A
AU  - Polo, E
AU  - Dotor, Emma
AU  - Duran-Ogalla, G
AU  - Rodriguez-Garrote, M
AU  - Calvo, A
AU  - Grande, E
AU  - Aranda, E
PY  - 2019
DO  - 10.1186/s12885-019-5753-7
SN  - 1471-2407
UR  - https://hdl.handle.net/20.500.12105/22655
AB  - Background: Treatment of frail patients with advanced colorectal cancer (CRC) is controversial. This pilot phase II trial aimed to assess the efficacy and safety of regorafenib when administered in first-line to frail patients with advanced CRC....
LA  - eng
PB  - BioMed Central (BMC)
KW  - Regorafenib
KW  - Colorectal cancer
KW  - Monotherapy
KW  - First-line
KW  - Frail patients
KW  - Elderly
TI  - First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
TY  - research article
ER  -